Cargando…

Ternatin and improved synthetic variants kill cancer cells by targeting the elongation factor-1A ternary complex

Cyclic peptide natural products have evolved to exploit diverse protein targets, many of which control essential cellular processes. Inspired by a series of cyclic peptides with partially elucidated structures, we designed synthetic variants of ternatin, a cytotoxic and anti-adipogenic natural produ...

Descripción completa

Detalles Bibliográficos
Autores principales: Carelli, Jordan D, Sethofer, Steven G, Smith, Geoffrey A, Miller, Howard R, Simard, Jillian L, Merrick, William C, Jain, Rishi K, Ross, Nathan T, Taunton, Jack
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4786417/
https://www.ncbi.nlm.nih.gov/pubmed/26651998
http://dx.doi.org/10.7554/eLife.10222
_version_ 1782420548184178688
author Carelli, Jordan D
Sethofer, Steven G
Smith, Geoffrey A
Miller, Howard R
Simard, Jillian L
Merrick, William C
Jain, Rishi K
Ross, Nathan T
Taunton, Jack
author_facet Carelli, Jordan D
Sethofer, Steven G
Smith, Geoffrey A
Miller, Howard R
Simard, Jillian L
Merrick, William C
Jain, Rishi K
Ross, Nathan T
Taunton, Jack
author_sort Carelli, Jordan D
collection PubMed
description Cyclic peptide natural products have evolved to exploit diverse protein targets, many of which control essential cellular processes. Inspired by a series of cyclic peptides with partially elucidated structures, we designed synthetic variants of ternatin, a cytotoxic and anti-adipogenic natural product whose molecular mode of action was unknown. The new ternatin variants are cytotoxic toward cancer cells, with up to 500-fold greater potency than ternatin itself. Using a ternatin photo-affinity probe, we identify the translation elongation factor-1A ternary complex (eEF1A·GTP·aminoacyl-tRNA) as a specific target and demonstrate competitive binding by the unrelated natural products, didemnin and cytotrienin. Mutations in domain III of eEF1A prevent ternatin binding and confer resistance to its cytotoxic effects, implicating the adjacent hydrophobic surface as a functional hot spot for eEF1A modulation. We conclude that the eukaryotic elongation factor-1A and its ternary complex with GTP and aminoacyl-tRNA are common targets for the evolution of cytotoxic natural products. DOI: http://dx.doi.org/10.7554/eLife.10222.001
format Online
Article
Text
id pubmed-4786417
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher eLife Sciences Publications, Ltd
record_format MEDLINE/PubMed
spelling pubmed-47864172016-03-17 Ternatin and improved synthetic variants kill cancer cells by targeting the elongation factor-1A ternary complex Carelli, Jordan D Sethofer, Steven G Smith, Geoffrey A Miller, Howard R Simard, Jillian L Merrick, William C Jain, Rishi K Ross, Nathan T Taunton, Jack eLife Biochemistry Cyclic peptide natural products have evolved to exploit diverse protein targets, many of which control essential cellular processes. Inspired by a series of cyclic peptides with partially elucidated structures, we designed synthetic variants of ternatin, a cytotoxic and anti-adipogenic natural product whose molecular mode of action was unknown. The new ternatin variants are cytotoxic toward cancer cells, with up to 500-fold greater potency than ternatin itself. Using a ternatin photo-affinity probe, we identify the translation elongation factor-1A ternary complex (eEF1A·GTP·aminoacyl-tRNA) as a specific target and demonstrate competitive binding by the unrelated natural products, didemnin and cytotrienin. Mutations in domain III of eEF1A prevent ternatin binding and confer resistance to its cytotoxic effects, implicating the adjacent hydrophobic surface as a functional hot spot for eEF1A modulation. We conclude that the eukaryotic elongation factor-1A and its ternary complex with GTP and aminoacyl-tRNA are common targets for the evolution of cytotoxic natural products. DOI: http://dx.doi.org/10.7554/eLife.10222.001 eLife Sciences Publications, Ltd 2015-12-10 /pmc/articles/PMC4786417/ /pubmed/26651998 http://dx.doi.org/10.7554/eLife.10222 Text en © 2015, Carelli et al http://creativecommons.org/licenses/by/4.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Biochemistry
Carelli, Jordan D
Sethofer, Steven G
Smith, Geoffrey A
Miller, Howard R
Simard, Jillian L
Merrick, William C
Jain, Rishi K
Ross, Nathan T
Taunton, Jack
Ternatin and improved synthetic variants kill cancer cells by targeting the elongation factor-1A ternary complex
title Ternatin and improved synthetic variants kill cancer cells by targeting the elongation factor-1A ternary complex
title_full Ternatin and improved synthetic variants kill cancer cells by targeting the elongation factor-1A ternary complex
title_fullStr Ternatin and improved synthetic variants kill cancer cells by targeting the elongation factor-1A ternary complex
title_full_unstemmed Ternatin and improved synthetic variants kill cancer cells by targeting the elongation factor-1A ternary complex
title_short Ternatin and improved synthetic variants kill cancer cells by targeting the elongation factor-1A ternary complex
title_sort ternatin and improved synthetic variants kill cancer cells by targeting the elongation factor-1a ternary complex
topic Biochemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4786417/
https://www.ncbi.nlm.nih.gov/pubmed/26651998
http://dx.doi.org/10.7554/eLife.10222
work_keys_str_mv AT carellijordand ternatinandimprovedsyntheticvariantskillcancercellsbytargetingtheelongationfactor1aternarycomplex
AT sethofersteveng ternatinandimprovedsyntheticvariantskillcancercellsbytargetingtheelongationfactor1aternarycomplex
AT smithgeoffreya ternatinandimprovedsyntheticvariantskillcancercellsbytargetingtheelongationfactor1aternarycomplex
AT millerhowardr ternatinandimprovedsyntheticvariantskillcancercellsbytargetingtheelongationfactor1aternarycomplex
AT simardjillianl ternatinandimprovedsyntheticvariantskillcancercellsbytargetingtheelongationfactor1aternarycomplex
AT merrickwilliamc ternatinandimprovedsyntheticvariantskillcancercellsbytargetingtheelongationfactor1aternarycomplex
AT jainrishik ternatinandimprovedsyntheticvariantskillcancercellsbytargetingtheelongationfactor1aternarycomplex
AT rossnathant ternatinandimprovedsyntheticvariantskillcancercellsbytargetingtheelongationfactor1aternarycomplex
AT tauntonjack ternatinandimprovedsyntheticvariantskillcancercellsbytargetingtheelongationfactor1aternarycomplex